Indications
Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.
Composition
- Active substance
- tucatinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tukysa
- Active substance
- tucatinib
- ATC code
- L01EH03
- Therapeutic area
- Breast Neoplasms, Neoplasm Metastasis
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status